While elevated VEGF-D levels are linked to incident AF and ischemic stroke in population studies [36], targeted therapeutic approaches (e.g., AdVEGF-DΔNΔC gene therapy) demonstrate enhanced myocardial perfusion without elevating arrhythmia risk [77,80]. The gene discussed is VEGFD; the disease is atrial fibrillation.